Identifying the Role of Protein kinase CK2 in the Radiosensitivity of Non-small Cell Lung Cancer

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:ljdoctor
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: Proteinkinase CK2 (also known ascasein kinase) is a highlyconserved seine/threonine protein kinase, which is ubiquitously expressed inmammalian cells.CK2 has been implicated in multiple physiological and pathological processranging from cell proliferation and survival to carcinogenesis.
其他文献
  Objective: IGNITE (a large, multinational, diagnostic, non-comparative, interventional study;NCT01788163) assessed EGFR mutation frequency in patients with
会议
  Objective: Although neoadjuvant chemotherapy (NAC) for advanced lung cancer can improve operability and local disease control, the duration of benefit is li
会议
  Objective: Central nervous system (CNS) progression is frequently detected in patients with favorable initial responses to Epidermal Growth Factor Receptor-
会议
  Objective: The central nervous system (CNS) is a frequent site of progression in ALK+ NSCLC patients treated with crizotinib, thus good CNS efficacy is of c
会议
  Objective: Lung cancer is the leading cause of cancer related death in the world.The last decade has witnessed the rapid development of epidermal growth fac
会议
  Objective: Tumor initiating cells (TICs) are a small subpopulation within cancer that is thought to be resistant to conventional therapiesand capable of rei
会议
  Objective: Stem-like cells in solid tumors are purported to contribute to cancer development and poor treatment outcome.The abilities to self-renew, differe
会议
  Objective: Patients (pts) with right middle lobe non-small cell lung cancer (NSCLC) were not well studied.This study analyzed the prognostic factors in rese
会议
  Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NS
会议
  Objective: Lung cancer is the leading cause of cancer-related deaths worldwide with 85% of non-small cell lung cancer (NSCLC) and squamous cell carcinomas (
会议